# Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer

> **NCT02263495** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 118 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Eribulin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02263495
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-19
- **Primary completion:** 2017-05-11
- **Final completion:** 2019-06-17
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02263495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02263495, "Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02263495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*